Zenas BioPharma Inc. (ZBIO)
Zenas BioPharma Statistics
Share Statistics
Zenas BioPharma has 41.79M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 41.79M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 1.24K |
| FTD / Avg. Volume | 0.63% |
Short Selling Information
The latest short interest is 3.22M, so 7.7% of the outstanding shares have been sold short.
| Short Interest | 3.22M |
| Short % of Shares Out | 7.7% |
| Short % of Float | 28.42% |
| Short Ratio (days to cover) | 7.68 |
Valuation Ratios
The PE ratio is -2.19 and the forward PE ratio is -1.76. Zenas BioPharma's PEG ratio is -0.01.
| PE Ratio | -2.19 |
| Forward PE | -1.76 |
| PS Ratio | 68.45 |
| Forward PS | 1.1 |
| PB Ratio | 1.1 |
| P/FCF Ratio | -2.86 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Zenas BioPharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.21, with a Debt / Equity ratio of 0.
| Current Ratio | 6.21 |
| Quick Ratio | 6.21 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $38.46K |
| Profits Per Employee | $-1.2M |
| Employee Count | 130 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -429K |
| Effective Tax Rate | 0.27% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -3.62, so Zenas BioPharma's price volatility has been lower than the market average.
| Beta | -3.62 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 7.62 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 46.91 |
| Average Volume (20 Days) | 196.91K |
Income Statement
In the last 12 months, Zenas BioPharma had revenue of 5M and earned -156.13M in profits. Earnings per share was -3.76.
| Revenue | 5M |
| Gross Profit | 5M |
| Operating Income | -163.89M |
| Net Income | -156.13M |
| EBITDA | -163.89M |
| EBIT | -163.89M |
| Earnings Per Share (EPS) | -3.76 |
Balance Sheet
The company has 319.74M in cash and 1M in debt, giving a net cash position of 318.74M.
| Cash & Cash Equivalents | 319.74M |
| Total Debt | 1M |
| Net Cash | 318.74M |
| Retained Earnings | -387.39M |
| Total Assets | 369.97M |
| Working Capital | 298.63M |
Cash Flow
In the last 12 months, operating cash flow was -119.67M and capital expenditures -131K, giving a free cash flow of -119.81M.
| Operating Cash Flow | -119.67M |
| Capital Expenditures | -131K |
| Free Cash Flow | -119.81M |
| FCF Per Share | -2.87 |
Margins
Gross margin is 100%, with operating and profit margins of -3277.76% and -3122.6%.
| Gross Margin | 100% |
| Operating Margin | -3277.76% |
| Pretax Margin | -3131.18% |
| Profit Margin | -3122.6% |
| EBITDA Margin | -3277.76% |
| EBIT Margin | -3277.76% |
| FCF Margin | -2396.1% |
Dividends & Yields
ZBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ZBIO is $32.5, which is 333.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $32.5 |
| Price Target Difference | 333.3% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 1.01 |
| Piotroski F-Score | 4 |